- Home
- SLS vs TVRD Comparison
SLS vs TVRD Comparison
Compare SLS & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- TVRD
- Stock Information
- Founded
- SLS 2012
- TVRD 2017
- Country
- SLS United States
- TVRD United States
- Employees
- SLS N/A
- TVRD N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- SLS Health Care
- TVRD Health Care
- Exchange
- SLS Nasdaq
- TVRD Nasdaq
- Market Cap
- SLS 238.7M
- TVRD 246.5M
- IPO Year
- SLS N/A
- TVRD N/A
- Fundamental
- Price
- SLS $1.92
- TVRD $4.87
- Analyst Decision
- SLS Strong Buy
- TVRD Buy
- Analyst Count
- SLS 1
- TVRD 7
- Target Price
- SLS $7.00
- TVRD $51.67
- AVG Volume (30 Days)
- SLS 4.7M
- TVRD 674.7K
- Earning Date
- SLS 11-12-2025
- TVRD 11-21-2025
- Dividend Yield
- SLS N/A
- TVRD N/A
- EPS Growth
- SLS N/A
- TVRD N/A
- EPS
- SLS N/A
- TVRD N/A
- Revenue
- SLS N/A
- TVRD N/A
- Revenue This Year
- SLS N/A
- TVRD N/A
- Revenue Next Year
- SLS N/A
- TVRD N/A
- P/E Ratio
- SLS N/A
- TVRD N/A
- Revenue Growth
- SLS N/A
- TVRD N/A
- 52 Week Low
- SLS $0.77
- TVRD $4.48
- 52 Week High
- SLS $2.48
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- SLS 51.34
- TVRD 19.82
- Support Level
- SLS $1.86
- TVRD $5.65
- Resistance Level
- SLS $2.06
- TVRD $7.23
- Average True Range (ATR)
- SLS 0.16
- TVRD 1.04
- MACD
- SLS -0.02
- TVRD -1.79
- Stochastic Oscillator
- SLS 11.90
- TVRD 1.00
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.